Literature DB >> 8912861

Activation of actin-cleavable interleukin 1beta-converting enzyme (ICE) family protease CPP-32 during chemotherapeutic agent-induced apoptosis in ovarian carcinoma cells.

Z Chen1, M Naito, T Mashima, T Tsuruo.   

Abstract

We have previously reported that actin cleavage activity (ACA) by interleukin 1beta-converting enzyme (ICE) family protease was elevated during anticancer drug-induced apoptosis in human leukemia U937 cells. In this study, the involvement of ACA in the drug-induced apoptosis in solid tumor cells was investigated. Human ovarian carcinoma OVCAR-3 cells undergo apoptotic cell death when cells are treated with chemotherapeutic agents such as cisplatin and etoposide. The induction of the actin cleavage activity accompanied the development of apoptosis. ICE/ced-3 family protease inhibitors such as Z-VAD-CH2DCB and Z-EVD-CH2DCB at 100 microg/ml prevented both the emergence of ACA and the morphological change, characteristics of apoptosis, in cisplatin-treated OVCAR-3 cells. The ACA in apoptotic OVCAR-3 cell lysate was greatly adsorbed by antibody against CPP-32, an ICE family protease. Furthermore, the immunoprecipitated CPP-32 from OVCAR-3 lysate could cleave actin to generate a 15-kDa fragment, as did the apoptotic OVCAR-3 cell lysate, indicating that CPP-32 is a major protease responsible for the ACA. The activation of CPP-32 in the drug-treated cell lysate was verified with Western blot analysis. Our present results indicate that CPP-32, an actin cleavage ICE/ced-3 family protease, could be a common mediator involved in the process of chemotherapy-induced apoptosis of cancer cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912861

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Actin cleavage in various tumor cells is not a critical requirement for executing apoptosis.

Authors:  R L Rice; D G Tang; J D Taylor
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 2.  Detection of actin cleavage in Alzheimer's disease.

Authors:  A LeBlanc
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

3.  Overexpression of caspase-1 in pancreatic disorders: implications for a function besides apoptosis.

Authors:  M Ramadani; F Gansauge; S Schlosser; Y Yang; H G Beger; S Gansauge
Journal:  J Gastrointest Surg       Date:  2001 Jul-Aug       Impact factor: 3.452

4.  Detection of programmed cell death using fluorescence energy transfer.

Authors:  X Xu; A L Gerard; B C Huang; D C Anderson; D G Payan; Y Luo
Journal:  Nucleic Acids Res       Date:  1998-04-15       Impact factor: 16.971

5.  Apoptosis resistance in tumor cells.

Authors:  T Mashima; H Seimiya; Z Chen; S Kataoka; T Tsuruo
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

6.  Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells.

Authors:  A Nehmé; R Baskaran; S Nebel; D Fink; S B Howell; J Y Wang; R D Christen
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

7.  Caspase-3 activation during apoptosis caused by glutathione-doxorubicin conjugate.

Authors:  T Asakura; T Sawai; Y Hashidume; Y Ohkawa; S Yokoyama; K Ohkawa
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

8.  EAT/mcl-1, a member of the bcl-2 related genes, confers resistance to apoptosis induced by cis-diammine dichloroplatinum (II) via a p53-independent pathway.

Authors:  T Ando; A Umezawa; A Suzuki; H Okita; M Sano; Y Hiraoka; S Aiso; T Saruta; J Hata
Journal:  Jpn J Cancer Res       Date:  1998-12

9.  Co-transduction of Apaf-1 and caspase-9 augments etoposide-induced apoptosis in U-373MG glioma cells.

Authors:  N Shinoura; S Sakurai; A Asai; T Kirino; H Hamada
Journal:  Jpn J Cancer Res       Date:  2001-04

10.  Potentiation of paclitaxel cytotoxicity by inostamycin in human small cell lung carcinoma, Ms-1 cells.

Authors:  S Simizu; K Tanabe; E Tashiro; M Takada; K Umezawa; M Imoto
Journal:  Jpn J Cancer Res       Date:  1998-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.